Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer

Martin Reck, Delvys Rodríguez‐Abreu, Andrew Robinson, +15

New England Journal of Medicine

Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer

Leena Gandhi, Delvys Rodríguez‐Abreu, Shirish M. Gadgeel, +26

New England Journal of Medicine

Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer

Edward B. Garon, Naiyer A. Rizvi, Rina Hui, +24

New England Journal of Medicine

Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer

Scott Antonia, Augusto Villegas, Davey B. Daniel, +27

New England Journal of Medicine

Pembrolizumab for Early Triple-Negative Breast Cancer

Peter Schmid, Javier Cortés, Lajos Pusztai, +18

New England Journal of Medicine

Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC

Scott Antonia, Augusto Villegas, Davey B. Daniel, +30

New England Journal of Medicine

Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater

Martin Reck, Delvys Rodríguez‐Abreu, Andrew Robinson, +15

Journal of Clinical Oncology

Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non–Small-Cell Lung Cancer

Shirish M. Gadgeel, Delvys Rodríguez‐Abreu, Giovanna Speranza, +23

Journal of Clinical Oncology

Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%

Martin Reck, Delvys Rodríguez‐Abreu, Andrew Robinson, +16

Journal of Clinical Oncology

Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

Miguel Martín, Frankie A. Holmes, Bent Ejlertsen, +617

The Lancet Oncology

5-Year AnalysisBreast OncologyOncologyHealth SciencesClinical Trials +8